Australian Schizophrenia Care and Assessment Programme: real-world schizophrenia: outcomes

References

• Nasrallah HA, Schwarzkopf SB, Olson SC, Coffman JA. Gender differences in schizophrenia on MRI brain scans. Schizophr Bull 1990; 16: 205–210
   PubMed Web of Science ®Google Scholar
• Attkisson C, Cook J, Karno M, et al. Clinical services research. Schizophr Bull 1992; 18: 561–626
   PubMed Web of Science ®Google Scholar
• Lehman AF. Evaluating outcomes of treatments for persons with psychotic disorders. J Clin Psychiatry 1996; 57(Suppl 11)61–67
   PubMed Web of Science ®Google Scholar
• Lehman AF, Fischer EP, Postrado L, et al. The Schizophrenia Care and Assessment Program Health Questionnaire (SCAP-HQ): an instrument to assess outcomes of schizophrenia care. Schizophr Bull 2003; 29: 247–256
   PubMed Web of Science ®Google Scholar
• Fitzgerald PB, Montgomery W, de Castella AR, et al. Australian Schizophrenia Care and Assessment Programme: real-world schizophrenia: economics. Aust N Z J Psychiatry 2007; 41: 819–829
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Faries D, Zhu B, Ernst F, Swartz M, Swanson J. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 2006; 67: 453–460
   PubMed Web of Science ®Google Scholar
• Burns T, Christova L, Cooper S, et al. Maintenance antipsychotic medication patterns in outpatient schizophrenia patients: a naturalistic cohort study. Acta Psychiatr Scand 2006; 113: 126–134
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–276
   PubMed Web of Science ®Google Scholar
• Montgomery S, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–389
   PubMed Web of Science ®Google Scholar
• First M. Effective use of the global assessment of functioning (GAF) scale in a managed care environment. Columbia University, New York 1996
   Google Scholar
• Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry 1988; 39: 1172–1177
   PubMedGoogle Scholar
• Simpson G, Angus J. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970; (Suppl 44): 11–19
   Google Scholar
• Heinrichs DW, Hanlon TE, Carpenter WT, Jr. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984; 10: 388–398
   PubMed Web of Science ®Google Scholar
• Hawthorne G, Richardson J, Osborne R. The Assessment of Quality of Life (AQoL) instrument: a psychometric measure of health-related quality of life. Qual Life Res 1999; 8: 209–224
   PubMed Web of Science ®Google Scholar
• Wertheimer AI. The defined daily dose system (DDD) for drug utilization review. Hosp Pharm ; :233–234, 239–241 1986; 21: 258
   PubMedGoogle Scholar
• Methodology. WCCfDS. ATC/DDD index 2005: about the ATC/DDD system. [Accessed 3 January 2006.] Available at URL: http://www.health.gov.au/casemix/costing/fc_r4.htm.
   Google Scholar
• Fitzgerald PB, De Castella AR, Filia KM, et al. A longitudinal study of patient- and observer-rated quality of life in schizophrenia Psychiatry Res 2003; 119: 55–62
   PubMed Web of Science ®Google Scholar
• Ciompi L. Learning from outcome studies. Toward a comprehensive biological–psychosocial understanding of schizophrenia. Schizophr Res 1988; 1: 373–384
   PubMed Web of Science ®Google Scholar
• Andrews G, Sanderson K, Corry J, Issakidis C, Lapsley H. Cost-effectiveness of current and optimal treatment for schizophrenia. Br J Psychiatry 2003; 183: 427–435
   PubMed Web of Science ®Google Scholar
• Andrews G, Issakidis C, Sanderson K, Corry J, Lapsley H. Utilising survey data to inform public policy: comparison of the cost-effectiveness of treatment of ten mental disorders. Br J Psychiatry 2004; 184: 526–533
   PubMed Web of Science ®Google Scholar
• Ragin AB, Pogue-Geile M, Oltmanns TF. Poverty of speech in schizophrenia and depression during in-patient and post-hospital periods. Br J Psychiatry 1989; 154: 52–57
   PubMed Web of Science ®Google Scholar
• Quinlan DM, Schuldberg D, Morgenstern H, Glazer W. Positive and negative symptom course in chronic community-based patients. A two-year prospective study. Br J Psychiatry 1995; 166: 634–641
   PubMed Web of Science ®Google Scholar
• Yuen O, Caligiuri MP, Williams R, Dickson RA. Tardive dyskinesia and positive and negative symptoms of schizophrenia. A study using instrumental measures. Br J Psychiatry 1996; 168: 702–708
   PubMed Web of Science ®Google Scholar
• Dollfus S, Petit M, Menard JF. Relationship between depressive and positive symptoms in schizophrenia. J Affect Disord 1993; 28: 61–69
   PubMed Web of Science ®Google Scholar
• Chalamat M, Mihalopoulos C, Carter R, Vos T. Assessing cost-effectiveness in mental health: vocational rehabilitation for schizophrenia and related conditions. Aust N Z J Psychiatry 2005; 39: 693–700
   PubMed Web of Science ®Google Scholar